
|Videos|January 6, 2014
Chemotherapy-Related Adverse Events Versus Immunotherapy-Related Adverse Events
Author(s)Matthew Burke, MBA, RN, MSN, APRN-BC
Matthew Burke, MBA, RN, MSN, APRN-BC, Oncology Nurse Practitioner/Melanoma and Renal Cell Carincoma, Yale New Haven Hospital, discusses the difference between adverse events caused by chemotherapy and immunotherapy.
Advertisement
Matthew Burke, MBA, RN, MSN, APRN-BC, Oncology Nurse Practitioner/Melanoma and Renal Cell Carincoma, Yale New Haven Hospital, discusses the difference between adverse events caused by chemotherapy and immunotherapy.
Clinical Pearls:
- Chemotherapy-related adverse events are usually limited to the time that the drug is in the patient’s body
- Immunotherapy agents cause modifications in the checkpoints of the immune system that may be permanent
- Because the immune system is altered during treatment, the severity of immunotherapy-related adverse events can be much worse than chemotherapy-related adverse events
- It is currently difficult to predict which patients will experience severe adverse events from immunotherapy treatment
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
3
Targeting HER2-Low Breast Cancer: the ARX788 Phase 2 Clinical Trial
4
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
5








































